Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America
Section snippets
Iron Deficiency: A Global Public Health Problem
Although iron is naturally abundant environmentally,1 iron deficiency (ID) is among the most common nutritional deficiencies worldwide.2 Although prehistoric skeletal remains have revealed findings consistent with prevalent ID,3 it was not until 1928 that Helen Mackay observed that infants with limited nutrition given supplemental iron salts experienced less postnatal hypochromic anemia and “looked healthier.”4 Recognition of inadequate dietary iron intake across the spectrum of age and
Operational Definition of ID
Iron exists in aqueous solution as ionized cytotoxic free radicals capable of causing oxidative injury and premature cell death and by necessity must be stored and transported throughout the body as protein–iron complexes.8,9 Most of the iron stored in the body is bound to ferritin, a cytosolic protein, predominantly located in the liver, spleen, skeletal muscles, and bone marrow although small amounts are constitutively released into the bloodstream (Fig. 1).10, 11, 12 Transferrin is a
Epidemiology of ID and Its Overlap With Anemia in HF
Early studies focused primarily on ID as a potentially reversible etiology of anemia, but there is now recognition that ID, independent of anemia, is a clinically relevant comorbidity that independently predicts prognosis in HF.5,31,32 The prevalence of anemia in HF based on World Health Organization criteria (ie, hemoglobin <12.0 g/dL in women and <13.0 g/dL in men) is approximately 30%–40%,33,34 whereas the prevalence of ID has been estimated to be closer to 40%–50%.5,35 Although the presence
Development of ID
Iron homeostasis in normal physiology and in the setting of chronic disease states is subject to a complex and dynamic regulation (Fig. 1). Although contributing factors may include, but are not limited to, reduced nutritional intake, systemic congestion and impaired intestinal absorption, and overt and/or occult blood loss, the pathogenesis of ID in HF is primarily owing to dysregulation of iron metabolism.5,31,32,35 Iron absorption and mobilization are both regulated by hepcidin, a protein
Functional Role of Iron and Clinical Manifestations of ID
Iron is a metabolically active micronutrient and is an important cofactor for enzymes and a key component of structural proteins.49, 50, 51, 52 Iron exists in bodily fluid as an ion in 2 oxidative states, bivalent ferrous (Fe2+) and trivalent ferric (Fe3+) iron, allowing it to serve as a catalyst for enzymatic reactions. However, iron's most pivotal role is in oxygen storage (ie, myoglobin), transport (ie, hemoglobin), and use at the cellular level (ie, oxidative enzymes and the electron
Oral Iron Formulations
Oral iron formulations are used routinely in the management of ID anemia owing to their ease of administration and low cost. However, limitations to oral iron supplementation include poor absorption, adverse effects, nonadherence, and delayed time to complete repletion.20 Formulations differ by their total iron content, excipients, cost, and tolerability. Iron salts are most commonly used and include ferrous fumarate, ferric gluconate, and ferrous sulfate. Polysaccharide iron complex, ferric
Discussion and Future Directions
The rapid evolution supporting the use of intravenous iron in patients with HF has led to raised awareness and need for adoption of its use in treatment in the most recent ACC/AHA/HFSA 2022 guidelines.83 As outlined above, both the 2013 guidelines and the 2016 focused update were void of any recommendation related to measuring iron levels or use of intravenous therapy.99, 100, 101 The 2022 guidelines make specific mention of collection of iron studies, including serum iron, ferritin, Tsat, and
Conclusions
ID is very common in HF, irrespective of the presence of anemia, and is associated with impaired functional capacity and poorer prognosis. Recently conducted clinical trials have shown that patients with HFrEF are relatively refractory to oral iron supplementation but do derive improvement in functional capacity and quality of life in response to intravenous iron repletion. Ongoing clinical trials will further reveal whether intravenous iron repletion improves functional capacity in HFpEF and
Lay Summary
It is not clear to us whether a lay summary is part of HFSA Scientific Statements but we will provide a Lay Summary upon request. Patients who have heart failure are likely to have lower than expected iron levels. This could led to symptoms, such as fatigue, and worsen outcomes. The use of iron replacement through a infusion has demonstrated improvement in symptoms.
Declaration of Competing Interests
None.
References (108)
- et al.
Criteria for iron deficiency in patients with heart failure
J Am Coll Cardiol
(2022) - et al.
Iron metabolism, free radicals, and oxidative injury
Biomed Pharmacother
(2001) - et al.
Two to tango: regulation of Mammalian iron metabolism
Cell
(2010) - et al.
Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue
J Am Coll Cardiol
(2003) - et al.
Iron deficiency in heart failure: an overview
JACC Heart Fail
(2019) - et al.
Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients
Pathology
(2007) - et al.
Relationship between soluble transferrin receptor and clinical outcomes in patients with heart failure according to ejection fraction phenotype: the New Zealand PEOPLE Study
J Card Fail
(2022) - et al.
2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary
J Card Fail
(2022) - et al.
A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia
Int J Cardiol
(2020) - et al.
Hepcidin and iron metabolism: from laboratory to clinical implications
Clin Chim Acta
(2010)
Iron uptake and metabolism in the new millennium
Trends Cell Biol
Iron regulatory proteins secure mitochondrial iron sufficiency and function
Cell Metab
Targeting the mitochondria in heart failure: a translational perspective
JACC Basic Transl Sci
Ultrastructural and cytochemical changes in the heart of iron-deficient rats
Biochem Pharmacol
Lethal cardiomyopathy in mice lacking transferrin receptor in the heart
Cell Rep
Metabolic catastrophe in mice lacking transferrin receptor in muscle
EBioMedicine
Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival
J Am Coll Cardiol
Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction
Int J Cardiol
Altered intestinal function in patients with chronic heart failure
J Am Coll Cardiol
Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women
Blood
Usefulness of oral ferric citrate in patients with iron-deficiency anemia and chronic kidney disease with or without heart failure
Am J Cardiol
2022 AHA/ACC/HFSA guideline for the management of heart failure
J Am Coll Cardiol
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
J Am Coll Cardiol
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
J Am Coll Cardiol
Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency
J Am Coll Cardiol
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial
J Am Coll Cardiol
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Lancet
Iron deficiency anemia: a common and curable disease
Cold Spring Harb Perspect Med
A new concept in the control of iron deficiency: community-based preventive supplementation of at-risk groups by the weekly intake of iron supplements
Biomed Environ Sci
Porotic hyperostosis: a new perspective
Am J Phys Anthropol
Anaemia in infancy: its prevalence and prevention
Arch Dis Child
Iron deficiency in chronic heart failure: an international pooled analysis
Am Heart J
Early history of iron deficiency
Br J Haematol
Disorders of iron metabolism
N Engl J Med
Molecular mechanisms of normal iron homeostasis
Hematology Am Soc Hematol Educ Program
Mammalian iron transport
Cell Mol Life Sci
Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis
J Clin Pathol
Ferritin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion
Arch Physiol Biochem
Chronic heart failure and inflammation: what do we really know?
Circ Res
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Eur Heart J
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency
Eur J Heart Fail
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches
Nat Rev Cardiol
Ferric carboxymaltose in patients with heart failure and iron deficiency
N Engl J Med
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
Eur Heart J
Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients
Circ Heart Fail
Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF Studies
JAMA Cardiol
Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients
Circ Heart Fail
Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review
J Gastrointestin Liver Dis
Serum transferrin receptor
Am J Hematol
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality
Eur J Heart Fail
Cited by (8)
Extending the Evidence for Intravenous Iron in Patients With Heart Failure and Iron Deficiency
2024, JACC: Heart FailureAcute Heart Failure: From The Emergency Department to the Intensive Care Unit
2024, Cardiology ClinicsSettling the IRONy of Anemia in Heart Failure: Current Evidence and Future Directions
2024, Journal of Cardiac FailureJCF Heart Failure Year-In-Review 2023… Shaping the Future of Heart Failure
2024, Journal of Cardiac FailureIron replacement therapy in heart failure: Contextualizing the results of the HEART-FID trial
2024, European Journal of Heart FailureFerric Carboxymaltose in Heart Failure with Iron Deficiency
2023, New England Journal of Medicine